US Patent
US8415355 — Pyrrolopyrimidine compounds and their uses
Composition of Matter · Assigned to Novartis AG · Expires 2031-03-13 · 5y remaining
Vulnerability score
10/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects novel pyrrolopyrimidine compounds and their uses, including pharmaceutical compositions and treatments for diseases associated with CDK 4 inhibition.
USPTO Abstract
The present invention relates to compounds of formula (I) and to pharmaceutically acceptable salts and pharmaceutical compositions thereof. The present invention also relates to use of the compounds of formula (I) in modulating the activity of protein kinases and in the treatment of disease, particularly a disease, disorder or syndrome associated with CDK 4 inhibition.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.